Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials

Abstract

PURPOSE. The purpose of this study was to investigate the use of imaging biomarkers in published clinical trials (CTs) in ophthalmology and its eventual changes during the past 10 years. METHODS.We sampled from published CTs in the fields of cornea, retina, and glaucoma between 2005-2006 and 2015-2016. Data collected included year of publication, phase, subspecialty, location, compliance with Consolidated Standards for Reporting Trials, impact factor, presence and use of imaging biomarkers (diagnostic, prognostic and predictive; primary and secondary surrogate endpoints), and use of centralized reading centers.RESULTS. We included 652 articles for analysis, equally distributed in three timeframes (2005-2006, 2010-2011, and 2015-2016), mainly reporting phase IV CTs and trials on procedures (42.2% and 35.4%, respectively). Imaging biomarkers were included in 46.3% of the analyzed CTs and their use significantly increased over time (P < 0.05). Optical coherence tomography was the most frequently used device (27.7%), whereas diagnostic biomarkers and secondary surrogate endpoints were the most frequent biomarker types (19.5% and 22.5%, respectively). Early-phase CTs showed an increase in the use of biomarkers for patient selection and stratification over time (P < 0.05), but not in the use of imaging surrogate endpoints (P ¼ 0.90). Only 3 of 59 (5.1%) of phase III CTs included primary surrogate imaging endpoints, whereas secondary surrogate imaging endpoints were present in 50.8% of these trials (P < 0.001). Retinal CTs had the highest prevalence for each type of imaging biomarker (P < 0.001). Reading centers were used in 52 of 302 CTs (17.2%), with no significant time-related increase.CONCLUSIONS. Imaging biomarkers are increasingly used in published CTs in ophthalmology. Additional efforts, including centralized reading centers, are needed to improve their validation and use, allowing a wider use of these tools as primary surrogate endpoints in phase III CTs.

Clinically Relevant Immune-Cellular Metrics of Inflammation in Meibomian Gland Dysfunction

“…The past decade has seen a steady rise in the application of imaging biomarkers across specialties within ophthalmic clinical trials. 48 While this trend is encouraging, a systematic, nationwide strategy focusing on establishing centralized image reading centers or the use of artificial intelligence needs to be institutionalized. Such establishments will help to ensure consistent methodology for standardization of metrics and subsequent validation of potential imaging biomarkers that can be stratified for types of ocular surface disease.…”

Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999–2017: Clinical efficacy considerations

“…37 Additional efforts, such as evidence-based consensus guidelines on relevant anatomical measures and use of centralised reading centres, are needed to improve their acceptability as primary surrogate end-points. 41…”

“…37 Additional efforts, such as evidence-based consensus guidelines on relevant anatomical measures and use of centralised reading centres, are needed to improve their acceptability as primary surrogate end-points. 41 For Izba (travoprost), no new efficacy data were submitted for the paediatric indication. Instead, a statistical modelling approach was used, referring to data from travoprost adult dose-response studies, the pivotal adult study for Izba (travoprost 0.003%), and the phase 3 paediatric trial of Travatan (travoprost 0.004%).…”

Imaging Biomarkers for Dry Eye Disease

“…2 Furthermore, the low success rate of recent clinical trials on DED, although due to several not yet fully understood concomitant factors, is pointing out the urgent need for the identification and validation of minimally invasive biomarkers to be used for patient selection and stratification and to monitor the response to the treatments. [3][4][5] Biomarkers and Surrogate Endpoints: Conceptual Framework and Updated Definitions…”